News

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.
The therapy achieved an overall response rate of 33%, exceeding the 20% threshold, with some patient groups achieving 50% ...
Time-limited (or fixed-duration) therapy offers a treatment-free interval, potentially leading to improved quality of life and reduced long-term toxicities. However, it may be less effective for ...
AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the company has also been expanding its offerings into solid tumors. Its ...
The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.
Grail announced that results from the registrational PATHFINDER 2 study of its Galleri multi-cancer early detection test showed that adding the test to standard-of-care screening resulted in ...